People: Invion Ltd (IVX.AX)

IVX.AX on Australia Stock Exchange

20 Nov 2019
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Collier, Gregory 

Dr. Gregory R. Collier, Ph.D. is re-designated as Non-Executive Director of the Company, effective 31 October 2019. He is no longer Chief Executive Officer, Managing Director, Executive Director of the Company, effective 31 October 2019. He has more than 20 years experience spanning operational, clinical and scientific aspects of pharmaceutical research, development and commercialization. He has led the planning and execution of multiple commercial transactions including in and out licensing deals and M&A activities, and he has taken a drug from discovery through to regulatory approval. Prior to his commercial pharmaceutical career, Dr. Collier had an academic career resulting in over 150 peer reviewed publications, and senior authorship on 33 patents. Dr Collier was the inaugural Alfred Deakin Professor at Deakin University, and also held positions at Melbourne University, Monash University and the University of Toronto. In 2010, Dr. Collier was awarded the Roche Award of Excellence for his contribution to the biotechnology industry.

Basic Compensation

Total Annual Compensation, AUD 46,739
Restricted Stock Award, AUD --
Long-Term Incentive Plans, AUD --
All Other, AUD 4,207
Fiscal Year Total, AUD 50,946

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --